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BACKGROUND AND PURPOSE
Tuberculosis (TB) remains a major global health threat and is now the leading cause of death from a single infectious agent
worldwide. The current TB drug regimen is inadequate, and new anti-tubercular agents are urgently required to be able to
successfully combat the increasing prevalence of drug-resistant TB. The purpose of this study was to investigate a piperidinol
compound derivative that is highly active against the Mycobacterium tuberculosis bacillus.
EXPERIMENTAL APPROACH
The antibacterial properties of the piperidinol compound and its corresponding bis-Mannich base analogue were evaluated
against M. smegmatis and Gram-negative organisms. Cytotoxicity studies were undertaken in order to determine the selectivity
index for these compounds. Spontaneous resistant mutants of M. smegmatis were generated against the piperidinol and
corresponding bis-Mannich base lead derivatives and whole genome sequencing employed to determine the genetic
modifications that lead to selection pressure in the presence of these compounds.
KEY RESULTS
The piperidinol and the bis-Mannich base analogue were found to be selective for mycobacteria and rapidly kill this organism with
a cytotoxicity selectivity index for mycobacteria of >30-fold. Whole genome sequencing of M. smegmatis strains resistant to the
lead compounds led to the identification of a number of single nucleotide polymorphisms indicating multiple targets.
CONCLUSION AND IMPLICATIONS
Our results indicate that the piperidinol moiety represents an attractive compound class in the pursuit of novel anti-tubercular
agents.
LINKED ARTICLES
This article is part of a themed section on Drug Metabolism and Antibiotic Resistance in Micro‐organisms. To view the other
articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.14/issuetoc
Abbreviations
CFU, colony forming units; CLint, intrinsic clearance; FIC, fractional inhibitory concentration; HIV, human
immunodeficiency virus; LB, Luria-Bertani; M. bovis BCG, Mycobacterium bovis bacillus Calmette-Guérin; MBC, minimum
bactericidal concentration; MIC, minimum inhibitory concentration; NAT, arylamine N-acetyltransferase; REMA,
resazurin microtiter assay; SNP, single nucleotide polymorphism; TB, tuberculosis; TE buffer, Tris-EDTA
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Introduction
Tuberculosis (TB), caused by the bacillus Mycobacterium
tuberculosis (M. tuberculosis), is a major global pathogen and
has now surpassed human immunodeficiency virus (HIV)
to be the leading cause of death from a single infectious
agent (WHO, 2015). In 2014, 9 million new cases of active
TB were reported and 1.5 million deaths resulted from TB
infection, with a significant number of deaths occurring in
individuals who are co-infected with HIV and TB (Dye and
Williams, 2010, WHO, 2015). The current drug regimen to
treat TB is over 40 years old and is hampered by its long
duration, which is typically 6–9 months in the case of
drug-sensitive strains and frequently accompanied by toxic
side effects (Zumla et al., 2015). A variety of reasons,
including patient non-compliance, have led to the
emergence of drug-resistant TB strains that are highly
resistant to most, if not, all – in the case of totally drug-
resistant strains of TB – of the current antibiotics that are
available (Udwadia et al., 2012, Klopper et al., 2013).
Together, this highlights the urgent need for the discovery
of new antibiotics that can be used to shorten treatment
time, tackle the increasing problem of clinical drug
resistance and be used in combination with HIV treatments.
However, there has been relatively little interest in the pursuit
of new therapeutic agents for TB by the pharmaceutical
industry, which may be due in part to the greatest burden
of disease being present in developing countries (Cole,
2014). Despite this, over the last 10 years, there has been
an increase in the discovery and development of new TB
drugs through either high-throughput phenotypic screens
or target-based approaches (Christophe et al., 2009,
Reynolds et al., 2012, Stanley et al., 2012, Lechartier
et al., 2014). This has resulted in a promising TB drug
pipeline (Zumla et al., 2013, Wallis et al., 2016),
comprising new antibiotic agents including the accelerated
approval of bedaquiline (Andries et al., 2005), which is the
first FDA-approved TB drug in 40 years, and delamanid,
for use in multidrug-resistant TB (Gler et al., 2012), along
with new therapeutic regimens (Zumla et al., 2013, Zumla
et al., 2015).
The mycobacterial N-acetyltransferase (NAT) enzyme has
been identified as a potential target for new TB agents (Bhakta
et al., 2004). Deletion of the nat gene in M. bovis bacillus
Calmette-Guérin (M. bovis BCG) results in a significant
decrease in the mycolates found in the mycobacterial cell
wall, with increased antibiotic susceptibility and killing
within macrophages (Bhakta et al., 2004, Anderton et al.,
2006). In previous work, a high-throughput target-based
screen of 5000 drug-like compounds was undertaken to find
specific inhibitors of NAT enzymes (Westwood et al., 2010,
Fullam et al., 2011, Abuhammad et al., 2012, Fullam et al.,
2013). From this screen, the piperidinol derivative: 3-
benzoyl-4-phenyl-1-methylpiperidinol (Figure 1), compound
1, was identified as an inhibitor of mycobacterial NAT
enzymes and a potent inhibitor of M. tuberculosis (Fullam
et al., 2008, Fullam et al., 2009, Westwood et al., 2010,
Abuhammad et al., 2012, Abuhammad et al., 2014). The
unique in vitromechanism of inhibition of compound 1 with
the NAT enzyme from M. marinum has been elucidated and
involves a specific covalent modification of a cysteine residue
located within the active site of the NAT enzyme (Fullam
et al., 2008, Fullam et al., 2009, Abuhammad et al., 2010,
Abuhammad et al., 2012).
The aim of this study was to further evaluate the
antimicrobial properties of the lead cyclic piperidinol
derivative 1 along with its analogous bis-Mannich base
derivative 2 (Figure 1), which, depending on the in vivo
physiological conditions encountered, may be produced via
a retro-aldol mechanism from compound 1. To achieve this
aim we undertook a combination of approaches involving
antimicrobial susceptibility testing, cytotoxicity studies,
resistancemapping bywhole genome sequencing and genetic
validation using the non-pathogenic organismM. smegmatis.
The combined results demonstrate that the piperidinol
scaffold 1 and its derivative 2 are specific for the
Mycobacterium genus, resulting in rapid killing, and have an
encouraging cytotoxicity selectivity index with multiple and
diverse mechanisms of action.
Figure 1
Compounds identified as inhibitors of the NAT enzyme. Structures of
piperidinol compound 1 and the bis-Mannich base compound 2.
Tables of Links
TARGETS
Enzymes
Arylamine N-acetyltransferase
LIGANDS
Compound 1 Rifampicin
Compound 2
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), or to the PubChem database. Links to the Guide to
PHARMACOLOGY are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015).
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Methods
Chemical synthesis of 4-hydroxy-1-methyl-4-
phenylpiperidin-3-yl)(phenyl)methanone:
compound 1, and 3,30-(methylazanediyl)bis(1-
phenylpropan-1-one): compound 2
The synthesis of 4-hydroxy-1-methyl-4-phenylpiperidin-3-
yl)(phenyl)methanone (compound 1) and 3,30-(methyla
zanediyl)bis(1-phenylpropan-1-one) (compound 2) was
carried out as described previously (Blicke and Burckhalter,
1942, Wang et al., 2000, Gul et al., 2002, Abuhammad et al.,
2012). Full experimental details and characterization data of
the compounds used in this study are in Supporting
Information Figures S1 and S2.
Bacterial strains, cell lines and culture
conditions
M. smegmatis MC2155 was routinely grown at 37°C in 7H9
broth (BD Difco, Oxford, UK) supplemented with 0.2%
glycerol and 0.05% Tween 80 or Luria-Bertani (LB) medium
supplemented with 0.05% Tween 80. Escherichia coli (E. coli)
and Pseudomonas putida (P. putida) were routinely cultured in
LBmediumat 37°C and 30°C respectively. Human alveolar basal
epithelial A549 cells (Public Health England, Porton Down, UK,
ECACC 86012804) were cultured at 37°C with 5% CO2
atmosphere in Ham’s F-12K (Kaighn’s) Medium (Gibco, Fisher
Scientific, Loughborough, UK) supplemented with 10% fetal
bovine serum, 100 units·mL1 penicillin, 100μg·mL1
streptomycin and 250 ng·mL1 amphotericin B (GE Healthcare
Hyclone, Little Chalfont, UK). Ovine red blood cells were
purchased from TCS Biosciences, Buckingham, UK.
Determination of MIC
The measurement of the minimum inhibitory concentration
(MIC) of compounds 1 and 2 was determined using the
resazurin reduction microplate assay (REMA) as described
previously (Palomino et al., 2002). M. smegmatis, E. coli and
P. putida were grown to mid-log phase, and the inoculum
was standardized to 1 × 106 colony forming units (CFU)·mL1
before addition to the prepared 96-well flat-bottommicrotiter
plate with twofold serial dilutions of each drug in media. An
antibiotic control was also added to each plate (rifampicin
for M. smegmatis, ampicillin for E. coli and tetracycline for
P. putida), and the last column of the plate was used as a
control without the addition of compound. In the case of
M. smegmatis, the plates were incubated for 24 h at 37°C
without shaking before an addition of 25 μL resazurin [one
tablet of resazurin (VWR) dissolved in 30 mL of sterile PBS].
Following a further incubation at 37°C, the plates were
assessed for colour development The MIC values were
determined as the lowest concentration of drug that
prevented the colour change of resazurin (blue – no bacterial
growth) to resorufin (pink – bacterial growth). The MIC
values were determined with five independent experimental
repeats, and data are presented as mean ± SEM.
Determination of the MBC
The minimum bactericidal activity (MBC) was determined by
setting up a microtiter plate as performed for the MIC
determination. Instead of adding resazurin at 24 h, each well
from the microtiter plate was plated on to solid LB medium
and the CFUs were determined after a 3 to 4 day incubation
at 37°C. The lowest concentration at which no CFUs were
counted was taken as the MBC. The MBCs were carried out
with five independent experimental repeats.
Time kill studies
Cultures of M. smegmatis (105 CFU) were incubated with 2×
MBC of compound 1 (625 μg·mL1), 2× MBC compound 2
(312.5 μg·mL1) and 2× MBC rifampicin (25 μg·mL1), along
with a no-drug control. Cultures were collected at defined
time intervals (0, 30, 60, 90, 120, 180, 240, 300 and
360 min and 24 h) and plated on solid LB media and
incubated at 37°C for 3 days. Cell viability was assessed by
determining the CFUs. The time kill studies were carried out
with five independent experimental repeats, and data are
presented as mean ± SEM.
Determination of compound interactions using
a REMA checkerboard assay
In order to determine whether the compounds interacted
with isoniazid, we employed a checkerboard assay. Fractional
inhibitory concentrations (FICs) were calculated by use of the
following formula: FIC (X + Y) = [MIC of compound X in
combination with Y]/[MIC of X alone]. To evaluate
interaction profiles, we calculated the fractional inhibitory
index (ΣFIC) as FIC of compound X + FIC of compound Y,
where ΣFICs of ≤0.5 designate synergistic activity, ΣFICs of
≥4.0 indicate antagonism and values in between correspond
to additivity (Rand et al., 1993, Lechartier et al., 2012).
Cytotoxicity assay
The cytotoxicity of the compounds was measured against a
human lung epithelial cell line (A549). Briefly, cells were
incubated (106 cells per well) with twofold serial dilutions
of compounds (compound 1: 31.25–500 μg·mL1, and
compound 2: 62.5–1000 μg·mL1) in a 12-well plate
(Thermo Fisher, #150628), including a cell-only control.
Following incubation for 24 h at 37°C, in the presence of
5% CO2, we determined cell viability by adding 100 μL
resazurin for 1 h at 37°C and measuring the absorbance of
the resofurin metabolite at 570 nm using a BioTek Synergy
HT microplate reader. All assays were undertaken with five
independent experimental repeats, and data are presented
as mean ± SEM.
Haemolysis assay
The haemolysis activity of compounds 1 and 2 was tested
against ovine red blood cells. Stock concentrations of
compounds 1 (500 μg·mL1) and 2 (1 mg·mL1) were
prepared in PBS containing 5% DMSO. The compounds were
serially diluted, giving final concentrations of compound 1 of
15.6–250 μg·mL1 and compound 2 of 31.25–500 μg·mL1. A
positive control comprised lysis buffer (10 mM Tris, pH 7.8,
0.32 M sucrose, 5 mM MgCl2, 10% Triton X-100), and the
negative control comprised PBS containing 5% DMSO.
Samples (150 μL) of each compound were added to 150 μL
of ovine blood and incubated at 22°C for 1 h, after which
the samples were centrifuged for 5 min (400 × g, 22°C). The
supernatant (10 μL) was added to 90 μL of PBS in a 96-well
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flat-bottom microtiter plate (Thermo Fisher, #167008) and
the absorbance read at 450 nm (BioTek HT Synergy). All
assays were undertaken with five independent experimental
repeats, and data are presented as mean ± SEM.
Agglutination assay
The agglutination activity of compounds 1 and 2 was
tested against ovine red blood cells. Briefly, 150 μL of ovine
blood was incubated with 150 μL compound 1 or 2
(twofold dilutions: final concentration of compound 1
15.6–250 μg·mL1 and final concentration of compound 2
31.25–500 μg·mL1). Separately, 150 μL of 25%
polyethylenimine was added as a positive control or 150 μL
PBS as a negative control. Following addition of the
compounds, we incubated the ovine blood at room
temperature for 1 h, afterwhich 50 μL of the samplewas added
to a round-bottom 96-well microtiter plate (Corning, #3790),
which was then incubated at room temperature for a further
30min. The plate was then assessed for signs of agglutination.
All assays were undertaken with five independent
experimental repeats, and data are presented as mean ± SEM.
Metabolic stability in vitro
The intrinsic clearance (CLint) of compounds 1 and 2 was
determined using mouse (CD-1) liver microsomes (Gibco).
Briefly, microsomes (100 μg final protein concentration) and
test compound in 0.1 M phosphate buffer, pH 7.4, were
prepared. In parallel, an NADPH-regenerating system
(Promega) was prepared in 0.1 M phosphate buffer (pH 7.4).
The solutions were pre-incubated at 37°C for 10 min before
assessment of the CLint was initiated by mixing the
two solutions (50 μL of each; final compound concentration
1 μg·mL) at 37°C. After 0, 5, 10, 15, 20 and 30 min, the
reactions were terminated by the addition of 100 μL of
acetonitrile containing 1 μg·mL1 verapamil and placed on
ice for 30 min. The samples were then centrifuged at
12 000× g for 10 min and analysed by LC–MS to determine
the quantity of the parent compound remaining over
time. Carbamazepine (1 μg·mL1) was used as a control for
low CLint.
Generation of spontaneous resistant mutants of
M. smegmatis to compounds 1 and 2
M. smegmatis resistant mutants were generated by plating 108
mid-log cells (OD600 0.6) on LB agar containing 2.5× MIC of
compound 1 and 5× MIC of compound 2. In the case of
compound 1, following the initial identification of mutants
from the initial 2.5× MIC plate, we inoculated the selected
colonies into liquid LB media containing 2× MIC compound
1 twice before selecting on solid medium containing 2.5×
MIC compound 1 and then proceeding as for compound 2.
In the case of compound 2, following identification, we
subsequently inoculated resistant mutants into liquid media
in the absence of the compound to mid-log phase and
selected on solid LB agar containing 5× MIC of compound
2. The colonies were subsequently inoculated into LB
medium in the absence of a compound before selecting on
LB agar plate containing either 2.5× MIC of compound 1 or
5× MIC of compound 2 to confirm resistance to the
compound. Following this validation step for the generation
and identification of spontaneous mutants, we inoculated
themutant strains and wild-typeM. smegmatis in parallel into
50 mL liquid media containing 2× MIC of the respective
compound (no compound was added in the case of the
wild-type M. smegmatis strain) and grew to mid-log phase.
Genomic DNA was prepared (total of nine samples: seven
resistant mutant strains and two wild-type strains) by
centrifugation of the culture and resuspension in 25%
sucrose, 50 mM EDTA, 50 mM Tris-HCl, pH 8.0 (SET
solution), and 50 μL of 20 mg·mL1 lysozyme and incubated
at 37°C for 16 h. After this incubation step, 5 μL of 10-
mg·mL1 RNase Awas added and the resuspension incubated
at 37°C for 30 min, after which 250 μL of Proteinase K
solution (400 mg·mL1, 100 mM Tris-HCl, pH 8.0, 0.5%
SDS) was added and incubated at 55°C for 2 h. DNA was
extracted using phenol–chloroform–isoamyl alcohol
(24:24:1) and chloroform–isoamyl alcohol (24:1),
precipitated with ethanol, dried by air and resuspended in
TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). The amount
and purity of the DNA were checked with a NanoDrop
(Thermo Scientific).
Genomic DNA from each M. smegmatis mutant and wild-
type strain was converted into Nextera XT libraries for
sequencing according to the manufacturer’s instructions
with a few modifications. Libraries were prepared using the
dual indexing principle and amplified libraries were purified
using 25 μL AMPure XP beads and 45 μL of purified library,
retained and stored at 20°C until denaturing for
sequencing. Libraries were pooled in equimolar con-
centrations (determined by analysis on Agilent Bioanalyser
2100 and HS dsDNA qubit assay) and 12 pM sequenced on
an Illumina MiSeq platform V2 2× 250 BP paired end
protocol. Reads were aligned to the M. smegmatis
MC2155 (accession number NC_008596.1) using the
Burrows–Wheeler Aligner MEM algorithm v0.7.5a-r405 (Li
and Durbin, 2009). Resulting BAM files were manipulated with
SAMtools (Li et al., 2009) to produce mpileup files, with the
following parameters ‘mpileup -B -f ’.VarScan v2.3 (Koboldt
et al., 2012) was used for single nucleotide polymorphism
(SNP) and insertion/deletion calling, with the following
parameters ‘ --min-var-freq .80 --P-value 0.05 --min-avg-qual
30’. SNPs that were common to both the wild-type control
and the mutant strain were not considered in further analysis.
Read data have been submitted to the EBI under the accession
number PRJEB15140.
Genetic validation
Genes identified as putative targets from the whole
genome sequencing data were cloned into the replicative
vector pMV261 for overexpression in mycobacteria under
control of the hsp60 promoter. The gene of interest was
amplified by PCR (Q5 High-Fidelity Polymerase;New England
Biolabs) from M. smegmatis genomic DNA. The primers used
are as shown in Supporting Information Table S1. The
resulting PCR product was digested with the appropriate
restriction enzymes and ligated (T4 DNA ligase, NEB) into
the pMV261 vector. The resulting construct was transformed
into E. coli TOP10 (Invitrogen) and verified by sequencing
(GATC Biotech). The resulting constructs were electroporated
into M. smegmatis along with an empty pMV261
vector control.
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Data and statistical analysis
The data and statistical analysis in this study comply with
the recommendations on experimental design and analysis
in pharmacology (Curtis et al., 2015). Blinding and
randomization were not applied in these experiments. All
data are shown as mean ± SEM of at least five individual
experiments and analysed using GraphPad Prism version
7.0a software program (GraphPad Software Inc., San Diego,
CA, USA). Statistical significance between different groups
was determined by unpaired t-test for two groups or one-
way ANOVA with Bonferroni’s post hoc test to compare all
pairs of columns for more than two groups. A value of
P < 0.01 was considered statistically significant.
Materials
Rifampicin was supplied by Carbosynth (Compton, UK);
ampicillin, carbamazepine, isoniazid, tetracycline and verapamil,
and all other chemicals were from Sigma Aldrich (Poole, UK)
Results
Antimicrobial properties of compound 1 and 2
Compound 1 has previously been shown to be highly active
against M. tuberculosis with an MIC of <5 μg·mL1 (Jeney
and Zsolnai, 1956, Abuhammad et al., 2012). We used the
REMA to determine the MIC for compound 1 and its bis-
Mannich base derivative 2 (Figure 1) against M. smegmatis.
In addition, in order to determine the specificity of
compounds 1 and 2 for the Mycobacterium genus, we also
tested these compounds for their potential to inhibit the
growth of the Gram-negative organisms E. coli and P. putida.
The MIC values for compounds 1 and 2 are shown in
Table 1 and indicate that the piperidinol class of compounds
and its corresponding bis-Mannich base are able to inhibit
the growth ofM. smegmatis with MIC values of 62.5 and 125-
μg·mL1 respectively.Whilst theMIC for compounds 1 and 2
is higher than that for M. tuberculosis, it is clear that these
compounds do not have any effect on the growth of E. coli
or P. putida at concentrations as high as 250 μg·mL1.
To further understand the inhibitory properties of
compounds 1 and 2, we determined the MBCs against
M. smegmatis. The MBCs were found to be 312.5 μg·mL1
for compound 1 and ranged between 78 and 156 μg·mL1
for compound 2, indicating that both compounds are
bactericidal against actively growing M. smegmatis. There is
good correlation between the MIC and MBC values for
compound 2, whereas compound 1 displayed an MBC 5×
greater than its MIC value.
To determine whether compounds 1 and 2 are able to kill
M. smegmatis completely and the rate at which the
antimicrobial activity is exerted, we conducted time kill
experiments in which the reduction of CFUs was quantified
as a function of exposure time of M. smegmatis to 2× MBC of
compounds 1 and 2 over a 24 h time period. The kill curve
is shown in Figure 2. A monophasic kill curve was observed
for both compounds 1 and 2 with a two-log reduction in
CFUs after 90 min for compound 1 and 3 h for compound 2
with apparently complete eradication of viable M. smegmatis
within 3 h for compound 1 and within 5 h for compound 2.
In comparison, rifampicin was added at 2× MBC, and no
reduction in CFUs were observed during this time (Figure 2)
(one-way ANOVA ).
Table 1
MICs of compounds 1 and 2
Bacterium Compound 1 MIC (μg·mL1) Compound 2 MIC (μg·mL1) Reference
M. tuberculosis 5 nd (Jeney and Zsolnai, 1956;
Abuhammad et al., 2012)
M. bovis BCG 6.25–12.5 nd (Abuhammad et al., 2014)
M. smegmatis 62.5 ± 0 125 ± 0 This study
E. coli 250 ± 0 250 ± 0 This study
P. putida 250 ± 0 >500 ± 0 This study
nd, not determined.
All assays in this study were undertaken with n = 5, and data are presented as mean ± SEM.
Figure 2
Time kill curve of compounds 1 and 2. Exponentially growing
cultures of M. smegmatis were treated with 2x MBC of compound
1, 2 and rifampicin. CFUs were counted at the time points indicated.
The averages of five independent experiments are shown and the
data are presented as mean ± SEM.
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Compound interaction assessed by a
checkerboard assay
To evaluate the impact of potential compound combinations
and interactions on M. smegmatis, we used a checkerboard
assay. Isoniazid was serially diluted twofold horizontally
across the plate (0–100 μg·mL1), and either compound 1 or
2 (0–1000 μg·mL1) was serially diluted twofold vertically
down the plate. We also used control wells in which
isoniazid, compound 1 or compound 2 alone were tested
(Supporting Information Figure S3). The sum of the fractional
inhibitory index (ΣFIC) for each combination was calculated,
whereby ΣFIC ≤0.5 denotes synergy and ΣFIC ≥4 denotes
antagonism. Compound 1 has a ΣFIC of 1.5 and compound
2 has a ΣFIC of 3. Importantly, no antagonistic interaction is
observed between either compound 1 or compound 2 and
the anti-tubercular agent isoniazid.
Cytotoxicity of compounds 1 and 2
To determine the selectivity index of compounds 1 and 2, we
measured the cytotoxicity of both compounds against the
A549 human lung epithelium cell line using the resazurin
reduction viability assay and the haemolytic activity of
compounds 1 and 2 against ovine red blood cells using both
a haemoglobin release assay and an agglutination assay
(Figure 3 and Supporting Information Figure S4). The
maximum tolerated dose of compounds 1 and 2 against A549
cells was found to be between 125 and 250 μg·mL1 (t-test)
(Figure 3A). No lysis or agglutination of ovine blood red
cells was observed at any of the concentrations tested
up to 250 μg·mL1 for compound 1 (t-test) and up to
500 μg·mL1 for compound 2 (t-test) (Figure 3B and
Supporting Information Figure S4). These results therefore
indicate that compounds 1 and 2 have a higher selectivity
for the clinically relevant pathogenic organismM. tuberculosis
compared with the human and ovine cells tested with a
selectivity index of >30-fold. These results are in agreement
with previous studies that also found low toxicity of
compound 1 for the mouse macrophage cell line RAW 264.7
and the human cell line U937 (Abuhammad et al., 2012).
Metabolic stability of compounds 1 and 2
We subsequently evaluated the in vitrometabolic stabilities of
compounds 1 and 2 using mouse liver microsomes and
LC–MS and found that both compounds had high CLint rates
>48 μL·min1·mg1 protein. A substrate known to have a
slow [CLint], carbamazepine, was used for comparison
(Supporting Information Figure S5).
Target identification of compounds 1 and 2
Compound 1 has shown encouraging inhibitory potency
against M. tuberculosis, and biochemical studies have shown
that compound 1 inhibits mycobacterial NAT enzymes
(Jeney and Zsolnai, 1956, Abuhammad et al., 2012,
Abuhammad et al., 2014). In order to identify any additional
intracellular targets for the piperidinol class of compounds,
we generated spontaneous resistant mutants inM. smegmatis.
Using the determined MIC values of compounds 1 and 2
(Table 1), we generated M. smegmatis resistant mutants on
solid LB agar containing 2.5× MIC of compound 1 (due to
solubility issues) and 5× MIC compound 2. Three colonies
for compound 1 and four colonies for compound 2 were
selected for subsequent inoculation in liquid medium in the
absence of any compound and reselection on solid medium
in the presence of either compound 1 at 2.5× MIC or
compound 2 at 5× MIC. All colonies selected from the
original plate maintained their ability to grow on solid
medium with the addition of compounds 1 and 2 following
this procedure. Two of the resistant mutants to compound 1
Figure 3
Cytotoxicity testing of compounds 1 and 2 against human A549 human lung epithelium cell line and ovine blood. (A) Effect on the cell viability of
the human A549 cell line in the presence of compound 1 or 2. A549 cells were exposed to compound 1 or 2 at the final concentrations indicated
for 24 h, and the cell viability was determined after this time by the addition of resazurin. Percentage cell viability is compared with an A549 cell-
only control. (B) Haemolysis of ovine red blood cells in the presence of compound 1 or 2. Ovine red blood cells were exposed to compound 1 or 2
at the final concentrations indicated for 1 h after which the percentage haemolysis was determined by measuring the absorbance at 450 nm.
Percentage lysis is compared with the 100% lysis after addition of lysis buffer (10 mM Tris, pH 7.8, 0.32 M sucrose, 5 mM MgCl2, 10% Triton
X-100). In both cases, the averages of five independent experiments are shown, and the data are presented as mean ± SEM.
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and two of the resistant mutants to compound 2 were
retested in the REMA. The results showed that the MIC of
the mutants to compound 1 increased fivefold (t-test) and,
to compound 2, the MIC of the mutants increased two- to
threefold (t-test), compared with the wild-type M. smegmatis
strain (Table 2). Interestingly, isolate 3 to compound 1 also
had increased resistance to compound 2 twofold to threefold
(t-test), and similarly, isolate 2 to compound 2 also increased
its resistance to compound 1 between twofold and threefold
(t-test), indicating cross-resistance and a potential common
resistance mechanism. Each mutant remained fully susce-
ptible to isoniazid and rifampicin (Table 2).
Given that resistance to compounds 1 and 2 was
maintained in the absence of any selection pressure on the
mutant strains generated, it was postulated that a genetic
resistance mechanism was involved in the observed resistant
phenotype. To identify the genetic mutation causing the
observed phenotype, we subjected the genomes of the
mutant strains to whole genome sequencing using Illumina
technology (Table 3).
Bioinformatics analysis identified 19 putative SNPs
compared with the laboratory M. smegmatis wild-type
control strains. Three SNPs were predicted to occur in
pseudogenes, six SNPs were predicted to occur in intergenic
regions and two SNPs were predicted as synonymous
mutations. Alleles with non-synonymous SNPs were found
to occur in sixM. smegmatis genes (Table 3) and included two
genes with unknown function (MSMEG_2746 and
MSMEG_3244), a gene predicted to be involved with homing
(HNH) endonuclease function (MSMEG_2148), a putative
3-dehydroquinate synthase gene (MSMEG_3033, aroB), a
putative monooxygenase gene (MSMEG_4083) and a putative
gene involved in amino acid transport (MSMEG_5807). It is
interesting to note that more alleles with non-synonymous
SNPs were identified for the resistant mutants isolated from
compound 2, which were generated at 5× MIC compound 2
compared with 2.5× MIC compound 1; this was due to
solubility issues encountered. It was particularly interesting
to find that four of the predicted SNPs occurred in the aroB
gene, resulting in an amino acid change of G278R and
Table 2
Activity of compounds 1 and 2 against selected resistant mutants
Isolatea
MIC compound 1
(μg·mL1)
MIC compound 2
(μg·mL1)
MIC INH
(μg·mL1)
MIC RIF
(μg·mL1)
Compound 1 1 375.0 ± 62.5 156 ± 0 25 ± 0 5 ± 0
Compound 1 3 375.0 ± 62.5 375.0 ± 62.5 12.5 ± 0 10 ± 0
Compound 2 1 171.6 ± 38.2 375.0 ± 62.5 12.5 ± 0 10 ± 0
Compound 2 2 265.6 ± 46.9 281.3 ± 31.3 12.5 ± 0 3.2 ± 0.5
n/a M. smegmatis WT 56.2 ± 6.3 112.5 ± 12.5 12.5 ± 0 3.2 ± 0.5
INH, isoniazid; RIF, rifampicin; WT, wild-type strain; n/a, not applicable.
The averages of five independent experiments are shown, and the data are presented as mean ± SEM.
aIsolate refers to mutant numbers listed in Table 3.
Table 3
SNPs detected in M. smegmatis mutants resistant to compounds 1 and 2
SNP locus M. smegmatis
chromosome position
Codon
Change
Amino acid
change Gene Annotation Compound 1 Compound 2
2223880 cCc ➔ cGc P380R MSMEG_2148 HNH endonuclease – – – – R R R
2223882 Aaa ➔ Caa K381Q – – – – K K K
2816638 gGa ➔ gAa G332E MSMEG_2746 Unknown E E – – E – –
3105561 Ggg ➔ Agg G278R MSMEG_3033 aroB – – – R R R R
3105568 gGc ➔ gAc G280D – – – – D D D
3105783 Tgc ➔ Ggc C352G – – – G G G G
3105805 cTa ➔ cCa L359P – – – – P P P
3328246a ccT ➔ ccC P384P MSMEG_3244 Hypothetical – – – – Pa Pa Pa
4158542a ttT ➔ ttC F227F MSMEG_4083 Monooxygenase – – – Fa Fa Fa Fa
5 874 050 gCc ➔ gGc A306G MSMEG_5807 Amino acid transport – G – – – – –
Genomic positions are relevant to M. smegmatis str. MC2155 (accession number NC_008596.1).
Wild-type alleles are represented by ‘–’.
aNon-synonymous SNP.
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C352G for all four resistant isolates to compound 2, and two
additional SNPs in aroB, resulting in the additional amino
acid change of G280D and L359P in three out of four of these
resistant isolates (Table 3). These results led us to investigate
the role of this potential aroB target further.
The aroB gene from M. smegmatis was expressed using the
hsp60 promoter from the replicative pMV261 vector and the
susceptibility of this overexpressing strain to compounds 1
and 2was assessed using the REMA and theMICs determined.
The results demonstrate that overexpression of aroB led to
partial resistance to both compounds 1 and 2when compared
with the wild-type strain (t-test), although there is little
difference between overexpression of aroB compared with
empty vector alone (Table 4).
Discussion and conclusions
The piperidinol (compound 1) and its corresponding bis-
Mannich base (compound 2) have previously been
demonstrated to have potent anti-tubercular activity against
both M. tuberculosis and M. bovis BCG (Jeney and Zsolnai,
1956, Abuhammad et al., 2012, Abuhammad et al., 2014) and,
here, we have shown these compounds also have specificity
for the Mycobacterium genus and good cytotoxicity selectivity.
Despite no evident signs of cytotoxicity, the compounds appear
to have a high CLint rate in mouse microsomes, and hence,
further chemical optimization of these compounds will be
required in order to improve their metabolic degradation
profile, while retaining anti-tubercular activity.
Treatment of TB is increasingly hindered by the
emergence of drug-resistant strains and this has led to
increased efforts in the identification of new potent
inhibitors of M. tuberculosis and pharmacologically validated
targets. In order to tackle this problem, there has been a
recent increase in the utilisation of chemical genomics
approaches to determine the cellular targets of these newly
identified anti-tubercular agents. The generation of
spontaneous resistant mutants followed by whole genome
sequencing has been successfully used to determine a
number of intracellular targets including, for example,
SQ109, an FDA approved drug to be used only for
drugresistant strains of TB (Tahlan et al., 2012),
dinitrobenzamide and benzothiazole derivatives which are
in the late stages of pre-clinical development (Christophe
et al., 2009, Neres et al., 2012) and the natural product
pyridomycin (Hartkoorn et al., 2012). From this approach a
range of new and previously pharmacologically validated
targets have been identified, including the MmpL3
membrane transporter (Tahlan et al., 2012) that is involved
in the export of trehalose monomycolate and cell wall
biosynthesis, and InhA, an enoyl-acyl carrier protein
reductase that is a key component in the type II fatty acid
synthase system (FasII) and is the cellular target for isoniazid
(Banerjee et al., 1994).
The piperidinol compound 1 inhibits the NAT enzyme
from M. marinum through the generation of a polyvinyl
moiety that forms a covalent adduct with the cysteine residue
located in the NAT active site (Abuhammad et al., 2010,
Abuhammad et al., 2012, Abuhammad et al., 2014). However,
the potential link between the anti-tubercular activity
observed for compound 1 and the potential endogenous role
of NAT in the bactericidal activity of this piperidinol
derivative has yet to be evaluated, and other potential targets
have not been excluded (Abuhammad et al., 2012,
Abuhammad et al., 2014). Therefore, in this study, we utilized
a chemical genetic approach as a route to determine other
potential cellular targets of compounds 1 and 2. Given that
M. smegmatis has been successfully used in high-throughput
screening campaigns to identify new TB drugs, including
the clinically approved anti-tubercular agent bedaquiline
(Andries et al., 2005), we chose to use this organism to
generate spontaneous resistant mutants due to the ease and
speed of manipulation despite the slight increase in the
MIC of compounds 1 and 2 compared to M. tuberculosis.
Interrogation of the genomes of the resultant resistant
isolates has led to the identification of a multiple number of
high-quality SNPs for eachmutant. The high number of SNPs
observed for this piperidinol scaffold is higher than that of
similar chemical bioinformatics studies (Hartkoorn et al.,
2012, Tahlan et al., 2012, Hartkoorn et al., 2014), suggesting
a potentially diverse profile of the mechanisms involved..
Mycobacteria have a unique cell wall structure,
comprising a mycolic acid–arabinogalactan–peptidoglycan
core (Brennan and Nikaido, 1995). Investigation into the
endogenous role of the NAT enzyme in mycobacteria by
deletion of the nat gene in M. bovis BCG has demonstrated
that NAT plays a key role in the biosynthesis of mycobacterial
mycolic acids and this enzyme has been postulated to have a
potential role in maintaining the homeostasis of the acetyl
CoA pool (Bhakta et al., 2004). NAT enzymes utilize the
cofactor acetyl CoA as an acetyl donor for arylamine
substrates (Sim et al., 2007). Although, under these
experimental conditions, our studies did not identify any
SNPs in the nat gene, it was of particular interest to note the
identification of a number of SNPs in the aroB enzyme in all
Table 4
Susceptibility profiles of M. smegmatis strains to compounds 1 and 2
MIC (μg·mL1)
Strain Compound 1 Compound 2 Rifampicin
M. smegmatis mc2155 – wild type 56.2 ± 6.3 112.5 ± 12.5 7.5 ± 1.1
M. smegmatis:aroB 112.5 ± 12.5 300.0 ± 49.9 7.5 ± 1.1
M. smegmatis:pMV261 112.5 ± 12.5 275.0 ± 61.2 7.5 ± 1.1
The averages of five independent experiments are shown, and the data are presented as mean ± SEM.
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resistant isolates generated with compound 2. The aroB gene
putatively encodes for a 3-dehydroquinate synthase enzyme
involved in the second step of the shikimate pathway with
AroB catalysing the cyclization of 3-deoxy-D-arabino-
heptulosonate-7-phosphate in 3-dehydroquinate. The
3-dehydroquinate is subsequently metabolized in the
shikimate pathway to chorismate, which is required for the
biosynthesis of all aromatic amino acids and other key
metabolites. In M. tuberculosis, the aroB gene (Rv2538) is
predicted to be essential for the survival of M. tuberculosis
(Parish and Stoker, 2002, Sassetti et al., 2003). Enzymes
within the shikimate pathway represent excellent targets for
the development of new antibiotics as they are essential for
bacterial survival but have no human counterpart (Bentley,
1990, Ducati et al., 2007). Given the role of the AroB
enzyme in the essential biosynthesis of aromatic amino
acids, naphthoquinones, menaquinones and mycobactin
in M. tuberculosis, we selected this prospective genetic target
for further validation. Overexpression of aroB using the
replicative pMV261 vector, with a relative copy number of
twofold to threefold (Stover et al., 1991), resulted in partial
resistance of these strains to compounds 1 and 2, which
could in part be explained by the presence of the
chromosomal wild-type aroB gene still being expressed.
Partial resistance has been found in a similar chemical
bioinformatics study to investigate the mechanism of
resistance to clofazimine, a drug that is used in the multidrug
therapy of leprosy (Hartkoorn et al., 2014), although it is
possible that these studies have also identified off-target
compensatory pathways in response to these compounds.
However, it is probable that given the high number of SNPs
identified for this piperidinol derivative for M. smegmatis,
these compounds are active against a diverse set of
intracellular targets, which subsequently results in difficulties
in restoring the observed chemical genetic phenotype
through overexpression of a single gene.
In summary, these studies indicate that the cyclic
piperidinol class of compound along with its bis-Mannich
base derivative is specific for the Mycobacterium genus and
rapidly kill M. smegmatis with encouraging cytotoxicity
profiles. Genetic interrogation of spontaneous resistant
mutants of M. smegmatis generated under the selective
pressure of compounds 1 and 2 has led to the identification
of potential genetic targets and pathways that are involved
in the multiple and diverse modes of action for these
piperidinol chemical moieties. Previous in vitro biochemical
studies demonstrated the formation of a polyvinyl ketone
moiety, which is likely to be highly reactive at the proteomic
level. Given the increase in TB drug-resistant strains that
often results from drugs acting on a single biological target,
chemical moieties with anti-tubercular inhibitory activities
that act upon multiple cellular targets are highly attractive,
from a clinical standpoint, for the development of new TB
agents and are worthy of further investigation.
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Figure S1 NMR characterisation of 4‐hydroxy‐1‐methyl‐4‐
phenylpiperidin‐3‐yl)(phenyl)methanone (1) in CDCl3: (A)
1H and (B) 13C spectra.
Figure S2 NMR characterisation of 3,3′‐(methylazanediyl)
bis(1‐phenylpropan‐1‐one) (2) in CDCl3: (A)
1H and (B) 13C
spectra.
Figure S3 M. smegmatis checkerboard assay of compound 1
and 2 with isoniazid. Minimum inhibitory concentrations
were determined for compound 1 and compound 2 with
and without isoniazid at the concentrations shown.
Fractional inhibitory concentrations (FICs) were determined
for each compound as the MIC of the compound alone
divided by the MIC of the compound in the presence of
isoniazid. The sum of the FICs was used to determine the
nature of the interactions.
Figure S4Ovine blood agglutination assay in the presence of
compound 1 and compound 2. The effect of compounds 1
and 2 on the agglutination of ovine blood was determined
at the concentrations indicated. The compounds were
incubated with ovine blood for 1 hour. A positive
agglutination control of 25 % polyethylenamine was added.
After this time the microtiter plate was assessed visually for
signs of agglutination. The experiment was carried out in
triplicate.
Figure S5 LC‐MS traces of the metabolic stability of
compounds 1 and 2 with mouse microsomes. A) compound
1 B) compound 2 C) carbamazepine. The stability of
compounds 1 and 2 (1 g/mL) were assessed in mouse
microsomes (100 g total protein) along with carbamazepine.
Samples were stopped at the time points indicated (0 – 30
mins) and analysed by LC‐MS in order to determine the
amount of parent compound remaining over time.
Table S1 Oligonucleotides used in these studies for
overexpression studies in M. smegmatis. Restriction
recognition sites are underlined.
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